Blockade of OSMRβ signaling ameliorates skin lesions in a mouse model of human atopic dermatitis

Abstract Atopic dermatitis (AD) is a chronic inflammatory skin disease characterized by severe pruritus and eczematous skin lesions. Although IL‐31, a type 2 helper T (Th2)‐derived cytokine, is important to the development of pruritus and skin lesions in AD, the blockade of IL‐31 signaling does not improve the skin lesions in AD. Oncostatin M (OSM), a member of IL‐6 family of cytokines, plays important roles in the regulation of various inflammatory responses through OSM receptor β subunit (OSMRβ), a common receptor subunit for OSM and IL‐31. However, the effects of OSM on the pathogenesis of AD remain to be elucidated. When AD model mice were treated with OSM, skin lesions were exacerbated and IL‐4 production was increased in the lymph nodes. Next, we investigated the effects of the monoclonal antibody (mAb) against OSMRβ on the pathogenesis of AD. Treatment with the anti‐OSMRβ mAb (7D2) reduced skin severity score in AD model mice. In addition to skin lesions, scratching behavior was decreased by 7D2 mAb with the reduction in the number of OSMRβ‐positive neurons in the dorsal root ganglia of AD model mice. 7D2 mAb also reduced the serum concentration of IL‐4, IL‐13, and IgE as well as the gene expressions of IL‐4 and IL‐13 in the lymph nodes of AD model mice. Blockade of both IL‐31 and OSM signaling is suggested to suppress both pruritus and Th2 responses, resulting in the improvement of skin lesions in AD. The anti‐OSMRβ mAb may be a new therapeutic candidate for the treatment of AD.